Biogen has entered into deals with two privately-owned companies, C4 Therapeutics (C4T) and Skyhawk Therapeutics, to bolster its early-stage neurology pipeline. The collaboration with C4T is to discover and develop treatments for neurological disorders such as Alzheimer’s disease and Parkinson’s disease, whereas the agreement with Skyhawk Therapeutics is to focus on multiple sclerosis and spinal muscular atrophy. The latter deal comes as Biogen’s multiple sclerosis franchise, including Tecfidera® (dimethyl fumarate), Avonex® (interferon beta-1a) and Tysabri® (natalizumab), faces declining sales amid increasing competition in the field.